CNBC·4 min read·hard
Novo Nordisk stock falls as raised outlook fails to change the debate over obesity business
E
Elsa Ohlen
✦AI Summary
Novo Nordisk shares fell despite the company raising its full-year guidance, as investors remain concerned about pricing pressure and competition in the obesity drug market. Analysts are questioning the long-term growth potential of the company's current pipeline.
Novo Nordisk 's CEO sought to reassure investors that its Wegovy pill can drive profitable growth despite lower prices, as investors sent the drugmaker's shares lower following quarterly results.
businesshealtheconomy
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in